PHERGain Clinical Trial
MedSIR will soon begin the PHERGain Clinical Trial (Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy), which may very well be our most ambitious medical research project in Oncology since we began in 2012.
Launching this phase II study –strategically developed from a clinical trial proposal idea generated by Drs. Antonio Llombart and Javier Cortés- is not only a great way to celebrate our 5th year anniversary, but also a wonderful opportunity to demonstrate how MedSIR strives to unite basic science, clinical research, and concern for patient benefit and quality of life. We believe this complete and multidisciplinary approach is the only way to go to make large steps towards a better future for breast cancer patients.
The goal of this multinational, open-label, randomized trial is to assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab, with or without endocrine therapy, on the primary tumor and their predictive value regarding pathological complete response (pCR). The study design will also allow researchers to define a set of patients that can achieve pCR without the need for chemotherapy. This would be an amazing achievement for many breast cancer patients worldwide.
Over 40 research sites -including some of Europe’s top centers and researchers in their field- in 6 European countries (Spain, France, UK, Germany, Italy, and Belgium) will participate in this groundbreaking trial that will enroll over 400 patients.
We would like to thank all those participating in the study as well as Roche for their financial support. For more information, please do not hesitate to contact us. We would love to help!